Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Regeneron
More »

  • Regeneron Gains Full Rights to Ophthalmology Antibodies from...
    Regeneron acquired full exclusive rights to two families of antibodies invented at the ... Acquired by Regeneron were full rights to antibodies targeting the PDGF (platelet derived ...
    5-3-2013
  • GEN | Biolinks
    ... Vegetal Redwood Bioscience, Inc Redx Pharma Ltd Regado Biosciences, Inc Regeneron Pharmaceuticals, Inc ReGenX Biosciences, LLC Regulus Therapeutics, Inc Reinnervate ...
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... 2012 sales: $32.3 million (€25 million) 11 Marketer(s): Sanofi and Regeneron Indication(s): Metastatic colorectal cancer in combination with 5-fluorouracil, ...
    4-4-2013
  • Cholesterol Drug Deal Worth Up to $205M
    PCSK9 proteins are the target of other drugs further along in development, including monoclonal antibody candidates from a Sanofi-Regeneron collaboration and from Amgen, the latter ...
    2-4-2013
  • Top 10 Clinical Trial Failures of 2012
    The bottom five, for which no writedowns have been announced, were listed alphabetically. #10. Zaltrap (aflibercept) Sponsor: Sanofi and Regeneron Pharmaceuticals Indication: ...
    2-1-2013
  • Biotech: A Model of Creative Acquisition
    ... companies-Regeneron, Onyx, and Dendreon-reported total revenues over $1.2 billion in 2011, increasing 1,700% from $67 million in 2005. Moreover, Regeneron reported $536 ...
    12-1-2012
  • Top 20 Molecular Millionaires
    ... 2012 Closing price: $89.01 #2. Leonard S. Schleifer, M.D., Ph.D. President and CEO, Regeneron Pharmaceuticals Total value of common shares owned: $257,315,504.13 2,119,393 common ...
    9-28-2012
  • Wet-AMD Therapy Approved in Japan
    Regeneron Pharmaceuticals confirmed Japanese regulatory approval of Eylea(tm) ... Bayer HealthCare and Regeneron are collaborating on global development of Eylea. Regeneron ...
    9-28-2012
  • GEN Reports on Ocular Therapeutics Targeting the Retina
    Standard therapy has been Genentech's VEGF inhibitors Lucentis® and the off-label use of Avastin®. Regeneron, in collaboration with Bayer HealthCare, is challenging these drugs ...
    9-6-2012
  • Ocular Therapeutics Target the Retina
    These are equally effective at improving vision, but the improvement only lasts six to eight weeks. Regeneron, in collaboration with Bayer HealthCare, is challenging these drugs ...
    9-1-2012
  • Top 25 Biotech Companies
    ... Cap: $9.09 billion (8/8: 274,555,930 shares * price $33.12) % Change: -2.4% #12. Regeneron 2012 Market Cap: $11.30 billion (7/13: 96,044,622 shares * price $117.64) 2011 Market ...
    8-17-2012
  • Looking for jobs at DDT
    Therapeutics (BMS), Altus Pharmaceuticals, EMD Serano, Millennium Pharmaceuticals, Novartis Vaccines & Diagnostics, Regeneron Pharmaceuticals and Shire Human Genetic Therapies. ...
    8-14-2012
  • Medarex Acquisition Ignites Broad Biotech Rally
    the sidelines. The bullish biotech investment script is intact. Stocks to watch are Cubist (CBST),Regeneron (REGN), Seattle Genetics (SGEN) and Viropharma (VPHM). | Rod Raynovich
    8-10-2012
  • Monoclonal Antibodies Enter Golden Age
    ... says Kevin Bailey, Ph.D., vp for preclinical manufacturing at Regeneron Pharmaceuticals. Regeneron develops monoclonal antibodies to block individual therapeutic targets ...
    8-1-2012
  • Santen Nabs Japanese Co-Promotion Rights to Bayer and Regeneron...
    Santen Pharmaceuticals negotiated co-promotion rights to Regeneron Pharmaceuticals and ... The deal with Santen means Bayer and Regeneron have in addition changed their previous 50/...
    5-8-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll